Jason Gerberry is ranked #1717 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Jason Gerberry (Bank of America Securities) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Jason Gerberry's stock ratings?

About 50% of Jason's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Jason Gerberry

BofA

Jason Gerberry

Bank of America Securities

Wall Street Analyst

★★★☆☆

#1717

on 13Foresight · ranked by our own returns

50%

Success Rate

+2.6%

Average Return

32 of 64 calls profitable · -4.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 50% of Jason Gerberry's ratings turned a profit when each position was held for 1 year — averaging +2.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

160 Buy 47 Hold 19 Sell

Jason's Stock Coverage 59 ratings · 2026-06-27

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
IONS Ionis Pharmaceuticals	Jun 24, 2026	BUY	Strong Buy +4.1% avg upside 43 analysts	$111.00 36.66% Upside	+3.1%
ABBV AbbVie	Jun 22, 2026	BUY	Buy -10.7% avg upside 44 analysts	$234.00 7.63% Downside	+5.7%
EXEL Exelixis	Jun 22, 2026	SELL	Buy -24.3% avg upside 33 analysts	$41.00 25.16% Downside	-0.0%
JAZZ Jazz Pharmaceuticals	Jun 10, 2026	BUY	Strong Buy -4.0% avg upside 35 analysts	$307.00 33.37% Upside	+0.8%
JNJ Johnson & Johnson	Jun 04, 2026	HOLD	Strong Buy -13.2% avg upside 36 analysts	$254.00 0.26% Downside	+11.6%
MRK Merck & Company	Jun 02, 2026	BUY	Strong Buy -1.6% avg upside 43 analysts	$130.00 1.01% Upside	+9.6%
OCS Oculis Holding	Jun 01, 2026	BUY	Strong Buy +220.5% avg upside 11 analysts	$35.00 191.72% Upside	-20.3%
BMRN BioMarin Pharmaceutical	May 29, 2026	BUY	Strong Buy +60.3% avg upside 52 analysts	$80.00 35.54% Upside	-2.4%
LLY Eli Lilly & Co	May 26, 2026	BUY	Strong Buy -17.2% avg upside 47 analysts	$1251.00 3.62% Upside	+1.7%
IMVT Immunovant	May 21, 2026	BUY	Strong Buy -0.5% avg upside 24 analysts	$43.00 10.74% Upside	+11.1%
BMY Bristol-Myers Squibb	May 20, 2026	BUY	Buy +2.8% avg upside 42 analysts	$67.00 16.46% Upside	-5.6%
LQDA Liquidia Technologies	May 14, 2026	BUY	Strong Buy -29.6% avg upside 15 analysts	—	+29.7%
GUTS Fractyl Health, Inc.	May 14, 2026	BUY	Strong Buy +523.7% avg upside 6 analysts	$2.00 169.14% Upside	-16.8%
LENZ LENZ Therapeutics	May 12, 2026	BUY	Buy +308.6% avg upside 17 analysts	$31.00 432.59% Upside	-13.7%
RPRX Royalty Pharma	May 07, 2026	BUY	Strong Buy -1.7% avg upside 15 analysts	$62.00 10.22% Upside	+9.4%
MLYS Mineralys Therapeutics, Inc.	May 07, 2026	BUY	Strong Buy +70.0% avg upside 12 analysts	—	-10.3%
TARS Tarsus Pharmaceuticals	May 07, 2026	BUY	Strong Buy +20.6% avg upside 16 analysts	—	-0.3%
PCVX Vaxcyte	May 07, 2026	BUY	Strong Buy +81.7% avg upside 15 analysts	—	-0.1%
AXSM Axsome Therapeutics	May 04, 2026	BUY	Strong Buy -7.2% avg upside 28 analysts	$276.00 14.25% Upside	+6.1%
TEVA Teva Pharmaceutical	Apr 30, 2026	BUY	Buy -11.6% avg upside 39 analysts	$40.00 20.39% Upside	-4.1%
ARWR Arrowhead Pharmaceuticals	Apr 20, 2026	BUY	Strong Buy -16.3% avg upside 26 analysts	$93.00 17.92% Upside	+18.1%
PFE Pfizer	Apr 09, 2026	HOLD	Buy +39.6% avg upside 45 analysts	$26.00 7.04% Upside	-6.3%
ALKS Alkermes	Apr 09, 2026	HOLD	Strong Buy -31.1% avg upside 34 analysts	—	+28.8%
UTHR United Therapeutics	Mar 30, 2026	HOLD	Strong Buy -19.7% avg upside 26 analysts	$626.00 15.43% Upside	-7.6%
XENE Xenon	Mar 09, 2026	BUY	Strong Buy +7.3% avg upside 28 analysts	$77.00 28.89% Upside	-13.0%
AMLX Amylyx Pharmaceuticals Inc	Mar 03, 2026	BUY	Strong Buy +34.4% avg upside 13 analysts	$19.00 6.85% Upside	+26.8%
HRMY Harmony Biosciences Holdings	Feb 24, 2026	SELL	Strong Buy +31.6% avg upside 13 analysts	$28.00 21.13% Downside	-6.7%
TSE:BHC Bausch Health Companies	Feb 18, 2026	SELL	Buy +784.5% avg upside 29 analysts	$7.09 4.70% Upside	·
OGN Organon	Feb 13, 2026	SELL	Sell +10.1% avg upside 9 analysts	—	-83.1%
VTRS Viatris	Jan 14, 2026	SELL	Buy +39.8% avg upside 21 analysts	$10.00 38.76% Downside	-24.1%
PROK ProKidney	Jan 12, 2026	SELL	Buy +260.7% avg upside 12 analysts	$1.00 45.27% Downside	+21.9%
CPRX Catalyst Pharma	Dec 08, 2025	BUY	Strong Buy -17.3% avg upside 15 analysts	$35.00 11.18% Upside	+35.6%
BHVN Biohaven Ltd.	Nov 10, 2025	HOLD	Buy +45.7% avg upside 25 analysts	$10.00 36.89% Downside	+103.2%
NL:LKFT Galapagos	Nov 07, 2025	SELL	Sell +105.7% avg upside 16 analysts	—	·
AMPH Amphastar Pharmaceuticals	Nov 07, 2025	HOLD	Hold +23.0% avg upside 11 analysts	—	-10.0%
LKFT Lakefront Biotherapeutics	Nov 06, 2025	SELL	Buy +257.2% avg upside 24 analysts	$28.00 5.02% Downside	·
RLAY Relay Therapeutics	Nov 06, 2025	BUY	Strong Buy +8.4% avg upside 19 analysts	$15.00 19.25% Downside	+143.2%
LYRA Lyra Therapeutics	May 23, 2024	HOLD	Hold +3733.3% avg upside 7 analysts	—	-71.9%
CHRS Coherus Biosciences	Oct 30, 2023	HOLD	Buy +737.6% avg upside 18 analysts	—	-75.1%
ALLO Allogene Therapeutics	Sep 28, 2023	HOLD	Strong Buy +616.3% avg upside 28 analysts	—	-14.7%
TVRD Tvardi Therapeutics	Aug 09, 2023	SELL	Buy +933.7% avg upside 23 analysts	$3.50 133.32% Upside	+88.5%
KYNB Kyntra Bio	Aug 08, 2023	SELL	Buy +335.7% avg upside 14 analysts	$2.00 72.34% Downside	+69.4%
BYSI Beyondspring	Jan 05, 2023	SELL	Hold +377.1% avg upside 8 analysts	$1.00 40.74% Downside	+49.7%
FNCHQ Finch Therapeutics Group	May 17, 2022	BUY	Strong Buy +142.2% avg upside 3 analysts	$11.00 4.89% Upside	·
VRCA Verrica Pharmaceuticals	Jul 15, 2020	HOLD	Strong Buy +167.3% avg upside 8 analysts	$10.00 46.18% Upside	+30.7%
VYNE VYNE Therapeutics	Mar 11, 2020	BUY	Strong Buy +1982.4% avg upside 9 analysts	$32.00 4835.94% Upside	-44.4%
ALNY Alnylam Pharma	Nov 13, 2019	BUY	Strong Buy +17.6% avg upside 51 analysts	$110.00 62.17% Downside	+49.6%
NBRVF Nabriva Therapeutics	Aug 20, 2019	BUY	Strong Buy +13374900.0% avg upside 9 analysts	$6.00 5999899.96% Upside	·
DE:MRK Merck KGaA	Jun 28, 2019	SELL	Buy -6.6% avg upside 33 analysts	—	·
SPRO Spero Therapeutics	Oct 16, 2018	SELL	Buy +517.2% avg upside 12 analysts	$9.00 298.27% Upside	-27.1%
ARDX Ardelyx	Nov 20, 2016	BUY	Strong Buy +137.9% avg upside 21 analysts	$18.00 224.31% Upside	-63.6%
HRTX Heron Therapeutics	Nov 15, 2016	BUY	Strong Buy +6284.2% avg upside 21 analysts	$34.00 7807.02% Upside	-23.1%
PCRX Pacira Pharmaceuticals	Nov 02, 2016	HOLD	Buy +54.5% avg upside 21 analysts	$37.00 46.61% Upside	-0.9%
PRGO Perrigo Company	Aug 10, 2016	HOLD	Buy +585.8% avg upside 20 analysts	$81.00 714.15% Upside	-10.0%
AMRX Amneal Pharmaceuticals	Aug 09, 2016	HOLD	Strong Buy -0.2% avg upside 18 analysts	$24.00 39.26% Upside	·
NVO Novo Nordisk	Aug 08, 2016	HOLD	Hold +142.0% avg upside 26 analysts	—	-10.1%
IRWD Ironwood Pharma	Aug 05, 2016	HOLD	Buy +188.8% avg upside 23 analysts	$14.00 238.92% Upside	+15.6%
NBIX Neurocrine	Jul 13, 2016	BUY	Strong Buy +2.0% avg upside 37 analysts	$70.00 58.47% Downside	+1.6%
CARM Carisma Therapeutics	Jan 19, 2016	HOLD	Buy +36011.1% avg upside 11 analysts	—	·

🔒 54 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jason Gerberry — Frequently Asked Questions

How accurate are Jason Gerberry's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Jason's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, or -4.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Jason ranked on 13Foresight?

Jason Gerberry is currently ranked #1717 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jason cover?

Jason most recently has ratings on IONS, ABBV, EXEL, JAZZ, JNJ, MRK, OCS, BMRN, LLY, IMVT, BMY, LQDA and 47 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!